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In an effort to structurally probe the metal binding
site in VanX, electronic absorption, EPR, and extended
x-ray absorption fine structure (EXAFS) spectroscopic
studies were conducted on Co(II)-substituted VanX.
Electronic spectroscopy revealed the presence of Co(II)
ligand field transitions that had molar absorptivities of
⬃100 Mⴚ1 cmⴚ1, which suggests that Co(II) is five-coordinate in Co(II)-substituted VanX. Low temperature
EPR spectra of Co(II)-substituted VanX were simulated
using spin Hamiltonian parameters of MS ⴝ 円ⴞ1⁄2典, E/D ⴝ
0.14, greal(x,y) ⴝ 2.37, and greal(z) ⴝ 2.03. These parameters
lead to the prediction that Co(II) in the enzyme is fivecoordinate and that there may be at least one solventderived ligand. Single scattering fits of EXAFS data indicate that the metal ions in both native Zn(II)containing and Co(II)-substituted VanX have the same
coordination number and that the metal ions are coordinated by 5 nitrogen/oxygen ligands at ⬃ 2.0 Å. These
data demonstrate that Co(II) (and Zn(II) from EXAFS
studies) is five-coordinate in VanX in contrast to previous crystallographic studies (Bussiere, D. E., Pratt, S. D.,
Katz, L., Severin, J. M., Holzman, T., and Park, C. H.
(1998) Mol. Cell 2, 75– 84). These spectroscopic studies
also demonstrate that the metal ion in Co(II)-substituted
VanX when complexed with a phosphinate analog of
substrate D-Ala-D-Ala is also five-coordinate.

Vancomycin is a cup-shaped glycopeptide that has been
called the “antibiotic of last resort” (1, 2) because it is often
used for antibiotic-resistant bacterial infections and in patients
who are allergic to penicillins. Vancomycin inhibits bacterial
cell wall synthesis by binding to the D-Ala-D-Ala end of the
peptidoglycan pentapeptide via five hydrogen bonds, thereby
preventing cross-linking of the cell wall precursors (3– 6). However, bacterial resistance to vancomycin in human pathogens
has emerged, particularly in Enterococcus and Staphylococcus
strains (3– 6). The genes responsible for inducible, high level
vancomycin resistance are carried on a 10-kb transposon,
which can be converted into self-transferable plasmids and
transferred by conjugation (7). The activities of five gene prod-
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ucts are required for high level resistance: VanR, VanS, VanH,
VanA, and VanX (5). VanR and VanS make up a two-component, signal transduction system that regulates the expression
of the other three genes and appears to be stimulated by the
presence of vancomycin (8 –10). VanH encodes for a D-specific
␣-ketoacid reductase, which catalyzes the reduction of pyruvate into D-lactate using NADPH (11, 12). VanA is a ligase that
uses the D-lactate produced by VanH and generates a D-Ala-Dlactate depsipeptide (11, 13). This depsipeptide is added to a
sugar-linked tripeptide by MurF, producing a modified bacterial cell wall precursor that can be incorporated into the growing peptidoglycan layer by the normal bacterial enzymes (3, 5,
12). Vancomycin binds to this modified cell wall pentapeptide
103 less tightly than to the normal pentapeptide due to the loss
of one hydrogen bond and to a key electrostatic repulsion (11,
14, 15). In other words, bacteria modify their peptidoglycan
layers to reduce the binding affinity of vancomycin, thereby
making the bacterium resistant to vancomycin.
The final gene product, VanX, is a D-Ala-D-Ala peptidase (16).
Walsh and co-workers (17–21) have reported the cloning, overexpression, and purification of VanX. VanX is a Zn(II)-binding
protein with a monomeric molecular mass of 23,365 Da that
hydrolyzes a very narrow range of substrates and does not
hydrolyze D-Ala-D-lactate or D-Ala-L-Ala (16, 17). Walsh and
co-workers (18) used site-directed mutagenesis studies to predict the metal binding amino acids, and these predictions were
confirmed when Bussiere and co-workers (1) published the
crystal structure of VanX. The mutagenesis study also implicated Arg-71 and Glu-181 as having roles in catalysis, and
these residues were shown in the crystal structure to be close to
the Zn(II) ion. The crystal structure also revealed that VanX
crystallized as a homohexamer, and each subunit bound one
Zn(II). The Zn(II) ion was coordinated in a distorted tetrahedral arrangement with the side chains of His-116, His-184, and
Asp-123 and a solvent water as ligands (Fig. 1). The crystal
structure also demonstrated a narrow cavity leading to the
active site (1), which nicely explained the very narrow substrate specificity of VanX.
Since VanX is essential for vancomycin resistance in bacteria, the enzyme has been targeted for drug/inhibitor design
studies in hopes that an inhibitor can be given in combination
with vancomycin as a treatment for vancomycin-resistant bacterial infections. Phosphinate and phosphonate analogs of DAla-D-Ala have been shown to be inhibitors of VanX, suggesting
that the enzyme utilizes a nucleophile-driven hydrolysis reaction that may proceed via a tetrahedral transition state intermediate (17, 22, 23). However, these structurally similar compounds exhibit Ki values varying over several orders of
magnitude, and the crystal structure of VanX complexed with
a phosphonate and a phosphinate demonstrated two distinct
binding interactions (1). Wu and Walsh (24) reported several
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FIG. 1. Active site of VanX (1). The
figure was rendered by Rasmol version
2.6.

dithiol compounds that exhibited potent, time-dependent inhibition of VanX, and Araoz et al. (25) reported that a modified
D-Ala-D-Gly dipeptide is a mechanism-based inactivator of
VanX. The former compounds apparently inhibit VanX by chelating Zn(II) and blocking access of the substrate. The latter
compound, upon hydrolysis by VanX, releases a reactive 4-thioquinonefluoromethide that reacts with a group on the surface
of the enzyme. Unfortunately none of the reported inhibitors
bind tightly enough or are specific enough to be useful as
clinical inhibitors.
One of the major obstacles in studying VanX is the lack of a
direct activity assay. The inability to find chromogenic substrates for VanX is presumably due to the narrow binding
cavity in the enzyme that leads up to the active site. The lack
of a direct activity assay complicates mechanistic studies, results from which could drive rational inhibitor design or redesign efforts. A ninhydrin-based assay, a capillary electrophoresis procedure, and several coupled assays have been reported
(17, 25–27); however, all of these have experimental problems
that limit their use in mechanistic studies. As an alternative,
we propose to follow the mechanism by preparing the Co(II)substituted form of VanX and probing the spectroscopic properties of the metal center during the catalytic cycle with use of
stopped-flow and rapid freeze quench coupled with spectroscopic studies. This work describes the preparation of Co(II)VanX and the biochemical and spectroscopic characterization
of the resulting enzyme.
MATERIALS AND METHODS

Preparation of Co(II)-substituted Maltose-binding Protein-VanX and
VanX—Co(II)-substituted maltose-binding protein (MBP)1-VanX and
VanX were prepared in minimal medium. The minimal medium contained 2.5 g/liter D-(⫹)-glucose, 5 g/liter casamino acids, 10.8 g/liter
K2HPO4, 5.5 g/liter KH2PO4, 10 g/liter NaCl, 1 g/liter (NH4)2SO4, 2
mg/liter thiamine, 1 mg/liter biotin, and a 1 ml/liter concentration of a
metal mixture containing 124 mg/liter MgSO4䡠7H2O, 74 g/ml
CaCl2䡠2H2O, 20 g/ml MnCl2䡠4H2O, 31 g/ml H3BO3, 1.2 g/ml
(NH4)6Mo7O24䡠4H2O, and 1.6 g/ml CuSO4 (28). In early preparations
the buffered medium was adjusted to pH 7.5 following a previously
reported protocol (28), but in later preparations, the medium was adjusted to pH 6.8 to increase the yields of Co(II)-VanX.
Plasmid pIADL14, containing the gene that encodes for a MBP-VanX
fusion protein (MBP-VanX), was a gift from Professor Christopher
1
The abbreviations used are: MBP, maltose-binding protein; EXAFS,
extended x-ray absorption fine structure; ICP-AES, inductively coupled
plasma with atomic emission spectroscopy.

Walsh at Harvard Medical School (18). The plasmid was transformed
into BL21(DE3) Escherichia coli cells, and colonies containing the plasmid were selected on Luria-Bertani (LB) agar plates containing 25
g/ml kanamycin. A single colony from this plate was used to make an
overnight preculture in minimal medium containing 25 g/ml kanamycin. Three 1-liter flasks, each containing 333 ml of minimal medium and
25 g/ml kanamycin, were inoculated with 10 ml of the overnight
preculture and were allowed to grow to an A600 nm of 1.6 –1.8 at 30 °C.
Protein production was induced by making the cultures 1 mM in isopropyl ␤-D-thiogalactopyranoside. At induction, the cultures were also
made 100 M in CoCl2. The cells were then collected by centrifugation
for 15 min at 8,275 ⫻ g, flash frozen in liquid N2, and stored at ⫺80 °C
overnight.
The cell pellets were thawed on ice and were resuspended in 30 mM
Tris-HCl, pH 7.6, containing 200 mM NaCl. Cells were lysed by passing
the resuspension two times through a French press at 16,000 p.s.i., and
the cellular debris were collected by centrifugation for 15 min at
32,583 ⫻ g. The cell lysate was then loaded on a 60-ml amylose column
(26 mm ⫻ 20 cm), and protein was eluted with a 0 –10 mM maltose
gradient over 300 ml in 30 mM Tris-HCl, pH 7.6, containing 200 mM
NaCl. Fractions containing MBP-VanX were identified by SDS-polyacrylamide gels, and pure fractions were pooled and concentrated to
⬃10 ml with an Amicon ultrafiltration concentrator equipped with a
YM-10 membrane. This overexpression/purification protocol resulted in
40 mg of MBP-VanX fusion protein/liter of growth culture. The maltosebinding protein from the fusion MBP-VanX protein was removed by
thrombin digestion. Three units of restriction grade thrombin were
added for every 1 mg of uncleaved MBP-VanX, and the cleavage was
allowed to incubate for 10 h in a water bath at 25 °C. The cleaved
proteins were then separated by two methods: a 120-ml Sephacryl
S-200 HR size exclusion column (16 mm ⫻ 60 cm) or a 25-ml QSepharose anion exchange column (16 mm ⫻ 20 cm).
Fractions containing purified, cleaved VanX, as judged by SDSPAGE, were pooled and concentrated using an Amicon ultrafiltration
concentrator equipped with a YM-10 membrane. VanX concentrations
were determined by using the sample’s absorbance at 280 nm, the
extinction coefficient (⑀280 nm), and Beer’s Law. The extinction coefficients of MBP-VanX (⑀280 nm ⫽ 115,700 M⫺1 cm⫺1) and VanX (⑀280 nm ⫽
51,200 M⫺1 cm⫺1) were determined with amino acid analyses performed
at the Protein Separation and Analysis Laboratory in the Department
of Biochemistry at Purdue University.
Steady-state Kinetic Studies—Steady-state kinetics were performed
using a coupled assay developed for VanX by Badet and co-workers (25).
This assay involves the use of other enzymes, such as D-lactate dehydrogenase (Sigma), catalase (Sigma), and D-amino-acid oxidase (Calzyme Laboratories). All enzymes other than VanX were kept in excess
so the rate-limiting process in the coupled reactions is the formation of
D-Ala by VanX. All reactions were conducted at 37 °C on an Agilent
8453 UV-visible spectrophotometer. Concentrations of reagents used in
the coupled assay were as follows: VanX at 1–5 nM, D-lactate dehydrogenase at 57 units/ml, catalase at 520 units/ml, D-amino-acid oxidase at
1.2 units/ml, NADH at 10 mM, and D-Ala-D-Ala was varied from 50 M
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to 2 mM with all solutions being made in 50 mM Hepes, pH 8.0, containing 200 mM NaCl. The reactions were monitored at 340 nm, and the
reactions were designed to ensure the loss of ⬃1 absorbance unit over
the course of 10 min. Absorbance values for the linear portion of the
curves were converted into velocities using the molar extinction coefficient for NADH (⑀340 nm ⫽ 6,220 M⫺1 cm⫺1) and the time interval of the
absorbance change. These values were then plotted against the corresponding substrate concentrations, and the resulting plots were fitted
to the Michaelis-Menten equation v0 ⫽ Vmax[S]/(Km ⫹ [S]) using Igor
Pro version 4.05A.
Metal Analyses—Metal analyses were performed using a Varian
Liberty 150 ICP-AES spectrometer. All purified enzyme samples were
diluted to ⬃10 M with 30 mM Tris-HCl, pH 7.6. A calibration curve
with four standards and a correlation coefficient of greater than 0.999
was generated using serial dilutions of Fisher metal standards. Three
trials of each sample were averaged. The following wavelengths for the
indicated metal ions were used to ensure the lowest detection limit
possible: zinc, 213.856 nm; copper, 324.754 nm; nickel, 321.604 nm;
cobalt, 238.892 nm; iron, 259.940 nm; and manganese, 257.610 nm.
Size Exclusion Chromatography—A 120-ml Sephacryl S-200 HR size
exclusion column was used to determine the molecular masses of MBPVanX and VanX. A calibration curve was used to relate molecular
weight to the retention time. The standard proteins were blue dextran
2000 (molecular mass, 2 MDa), thyroglobulin (molecular mass, 669
kDa), ferritin (molecular mass, 440 kDa), catalase (molecular mass, 232
kDa), aldolase (molecular mass, 158 kDa), and albumin (molecular
mass, 67 kDa). The mobile phase buffer was 0.05 M Na3PO4, pH 7.6,
containing 150 mM NaCl, and the flow rate was 0.5 ml/min. Analysis of
protein location was conducted using UV-visible spectroscopy measuring the absorbance at 280 nm of every 2-ml fraction.
UV-Visible Spectroscopy—All UV-visible spectra were collected on an
Agilent 8453 UV-visible spectrophotometer with photodiode array detection measuring the UV-visible absorbance at each wavelength between 200 and 1,100 nm. Enzyme concentrations ranged from 200 M to
1 mM, and enzyme samples were loaded in a 0.5-ml quartz cuvette. The
buffer used for dilutions and for the blanks was 30 mM Tris-HCl, pH 7.6.
Spectra were recorded at 25 °C. The phosphinate inhibitor (22, 23)
D-3-[(1-aminoethyl)phosphinyl]-2-methylpropionic acid was synthesized by Dr. Ke-Wu Yang and was dissolved in 50 mM Hepes, pH 8.0.
The solution of inhibitor was added directly to the VanX samples.
EPR Spectroscopy—All EPR spectra were obtained on a Bruker Instruments ER 300 EPR spectrometer equipped with an ER 035M NMR
gaussmeter and a Hewlett Packard 5352B microwave frequency counter. Spectra were recorded at various temperatures between 4 and 16 K
using an Oxford Instruments liquid helium-cooled cryostat. Spectra
were recorded with the following conditions: 2-milliwatt microwave
power, 9.48-GHz microwave frequency, and 10-G modulation amplitude
at 100 kHz. Conditions were chosen so as to be non-saturating. Spectra
were integrated, and the base line was examined to verify that spectral
distortion due to passage effects did not occur. Samples in solution were
pipetted into 4-mm outer diameter quartz EPR tubes and then flash
frozen in liquid nitrogen. Precipitated VanX samples were centrifuged,
and the supernatant was decanted. A small volume of 30 mM Tris, pH
7.6, was added, and the solid was resuspended. The resulting slurry
was then pipetted into an EPR tube and flash frozen.
EPR spectra were simulated with the program XSophe (Bruker),
assuming a spin Hamiltonian H ⫽ ␤g䡠S䡠H ⫹ S䡠D䡠S with S ⫽ 3/2 and
where D ⬎ 0 corresponds to an MS ⫽ 兩⫾1⁄2典 ground state Kramers’
doublet. For Co(II), 兩D兩 is usually much greater than the Zeeman interaction (29); with 兩D兩 ⬎⬎ ␤gSH, the simulations are insensitive to the
precise magnitude of D and an arbitrary value of D ⫽ 50 cm⫺1 was
assumed. The useful EPR parameters that can be extracted from the
simulations are greal and E/D (30).
X-ray Absorption Spectroscopy—MBP-VanX samples were concentrated to ⬃1 mM using ultrafiltration and were prepared with 30% (v/v)
added glycerol as glassing agent. Samples were loaded in Lucite cuvettes with 6-m polypropylene windows and frozen rapidly in liquid
nitrogen. X-ray absorption spectra were measured at the National
Synchrotron Light Source, beamline X9B, with a silicon(111) double
crystal monochromator; harmonic rejection was accomplished using a
curved nickel focusing mirror. Fluorescence excitation spectra for all
samples were measured with a 13-element solid-state germanium detector array. The detectors were run at a total incident count rate of
⬍100 kHz per channel with fluorescence count rates (K␣) of ⬃ 1.5 kHz
per channel. Samples were held at or below 15 K in a Displex cryostat
during X-ray absorption spectroscopy measurements. EXAFS spectra
were measured with 10-eV steps below the edge, 0.5-eV steps in the
edge region, and 0.05-Å⫺1 steps in the EXAFS region. Integration times

varied from 1 s in the pre-edge region to 13 s at k ⬇ 12 Å⫺1. X-ray
energies were calibrated by reference to the absorption spectrum of the
appropriate metal foil measured concurrently with protein spectra. The
first inflection point of the metal foil was assigned as the K␣ binding
energy: 7,709 eV for cobalt and 9,659 eV for zinc.
Data were processed using SixPack (SixPack is available free of
charge from www-ssrl.slac.Stanford.edu/⬃swebb/sixpack.htm). Both
fluorescence and incident count rates from each detector channel were
examined, to confirm the absence of artifacts, prior to averaging. Final
spectra were obtained by averaging four to six scans per sample with
the inclusion of 10 –12 detector channels per scan. Background subtraction included a Gaussian pre-edge, centered at approximately the K␣
fluorescence energy, and a three-region spline of fourth order in the
EXAFS region. Data were converted from energy to k space using k ⫽
公2me(E ⫺ E0/ប2 with E0 set at 7,745 eV (cobalt) or 9,675 eV (zinc).
Resultant EXAFS spectra were Fourier-transformed over the range k ⫽
1–12.1 Å⫺1 (cobalt) or 1–13.6 Å⫺1 (zinc). The first shell (r ⫽ 0.6 –2.2 Å
(cobalt), r ⫽ 0.7–2.1 Å (zinc)) was reverse Fourier-transformed over the
same k range. The Fourier-filtered first shell EXAFS (⬃10 degrees of
freedom) data were fitted to Equation 1 using the nonlinear leastsquares engine of IFEFFIT (IFEFFIT is available free of charge from
cars9.uchicago.edu/ifeffit and is distributed with SixPack).
 共k兲 ⫽

冘

N asAs(k)Sc
exp(⫺2k2as2)exp(⫺2Ras/)sin[2kRas ⫹ as(k)]
kRas2

(Eq. 1)

In Equation 1, Ns is the number of scattering atoms within a given
radius (Ras ⫾ ), As(k) is the backscattering amplitude of the absorberscatterer (as) pair, as(k) is the phase shift experienced by the photoelectron as it encounters the electron clouds of the scattering and
absorbing atoms,  is the photoelectron mean free path, and the sum is
taken over all shells of scattering atoms. Theoretical amplitude and
phase functions, As(k)exp(⫺2Ras/) and as(k), were calculated using
FEFF version 8.00 (31). Optimal absorber-scatterer-specific scale factors, Sc, were determined by fitting experimental spectra for compounds
of known structure (0.78 for CoON from cobalt(II) trispyrazolylborate
(32) and 0.74 for ZnON from zinc(II) tetrakisimidazole (33)). Fits to
protein data were then obtained for all reasonable integer coordination
numbers holding Sc fixed and allowing ⌬E0, Ras, and as2 to vary. The
best all nitrogen fits are summarized in Table II. Similar results were
obtained using a single shell of oxygen atoms to model the first shell.
Markedly better fit residuals were obtained with mixed nitrogen/oxygen models; however, the data do not possess sufficient degrees of
freedom to warrant the use of multiple atom types, and these fits are
not reported.
RESULTS

Preparation and Characterization of Co(II)-substituted
VanX—Our initial efforts to prepare Co(II)-substituted VanX
involved using the direct addition method as described by Auld
(34, 35). In our case, this method involved the removal of
naturally occurring Zn(II) by dialysis versus chelators and the
addition of Co(II) to apoVanX. Despite considerable efforts, we
could not use this method to prepare Co(II)-substituted VanX
in concentrations sufficient for spectroscopic studies as the
protein precipitated during dialysis and concentration steps,
and frequently Co(II) oxidized to Co(III) during the steps.
Therefore, a biosynthetic method to prepare Co(II)-substituted VanX was used (28, 35). By using a previously published
method for the preparation of VanX as a fusion protein with
MBP (18), Co(II)-substituted VanX was overexpressed in minimal medium supplemented with 100 M CoCl2 and purified
using an amylose affinity column. The MBP-VanX fusion protein was cleaved with thrombin, and the cleaved proteins were
separated by using size exclusion or ion-exchange chromatography. VanX eluted from the size exclusion column earlier than
MBP despite VanX having a monomeric molecular mass of 23
kDa and MBP having a molecular mass of 42 kDa. This result
suggests that VanX aggregates in solution into a species with a
molecular mass greater than 42 kDa. To further test this hypothesis, size exclusion chromatography was used to determine
the quaternary structures of VanX and MBP-VanX. Both proteins eluted from the column right after blue dextran and had
elution times consistent with molecular masses of 500 and 630
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TABLE I
Steady-state kinetic constants and metal content of VanX samples
Steady-state kinetic constants were determined using the coupled assay (25), and metal content was determined by ICP-AES.
Enzyme

kcat

KM

⫺1

M

s

a
b

Zn(II)-VanX

41 ⫾ 2

110 ⫾ 10

Zn(II)-VanX
Co(II)-VanX

156 ⫾ 16
94 ⫾ 6

109 ⫾ 40
140 ⫾ 40

MBP-Co(II)-VanX

110 ⫾ 20

100 ⫾ 40

Source

eq

NRa
0.87b Zn(II)
0.70 ⫾ 0.02 Zn(II)
0.06 ⫾ 0.03 Zn(II)
0.60 ⫾ 0.09 Co(II)
0.06 ⫾ 0.03 Zn(II)
0.66 ⫾ 0.09 Co(II)

Ref. 25
Our data
Our data
Our data

Not reported.
Reported in Ref. 18.

kDa, respectively. The elution profile was unaffected by the
inclusion of dithiothreitol or higher concentrations of salt in the
buffer. The result with the reductant was not surprising since
the crystal structure of hexameric VanX showed that disulfides
are not involved in the aggregation of VanX.2 This result suggests that MBP-VanX, in the buffers and at the concentrations
used in our studies, has a decameric structure, while VanX is
composed of over 20 monomers. Efforts to concentrate these
samples show that MBP-VanX can be concentrated to 1.6 mM,
while VanX can only be concentrated to 0.3 mM.
The steady-state kinetic properties of Co(II)-substituted
VanX and MBP-VanX were determined using the optimized
coupled assay of Badet and co-workers (25) (Table I). Co(II)substituted VanX exhibited kcat and Km values of 94 ⫾ 6 s⫺1
and 140 ⫾ 40 M, respectively, and these values were similar to
those of the fusion protein Co(II)-MBP-VanX (kcat ⫽ 110 ⫾ 20
s⫺1 and Km ⫽ 100 ⫾ 40 M). It is clear that the presence of MBP
does not affect the steady-state kinetic constants exhibited by
VanX in agreement with previous reports (18). The Co(II)substituted analogs of VanX exhibited Km values identical to
Zn(II)-VanX and a 70% reduction in kcat values, which is common for Co(II)-substituted enzymes (36). In our experiments,
the kcat value for Zn(II)-VanX was 3-fold higher than that
previously reported (25). It is possible, in the previous report
(25), the rate of D-amino-acid oxidase contributed to the overall
rate of reaction attributed to VanX.
Metal analyses on VanX produced from the MBP fusion
construct showed that the isolated enzymes bind roughly
0.70 ⫾ 0.02 equivalents of only cobalt or zinc. No other metal
ions were found in the VanX samples. The inclusion of higher
concentrations of Zn(II)/Co(II) in the growth medium used for
overexpression did not result in purified VanX samples with
more equivalents of metal ions. If excess Zn(II) or Co(II) was
added to the as-isolated VanX (or MBP-VanX) and the enzymes
were exhaustively dialyzed versus metal-free buffer, the resulting enzymes contained 1.0 ⫾ 0.1 metal ion per monomer. We
were unable to isolate Co(II)-substituted VanX that contained
less than 0.06 equivalents of Zn(II), most likely due to Zn(II)
from buffers, growth medium, glassware, etc.
Electronic Spectra of Co(II)-substituted VanX—The UV-visible spectrum of Co(II)-substituted MBP-VanX shows three
peaks at 520, 550, and 580 nm and no other features above 300
nm (Fig. 2A). The peak at 580 nm often appears as a shoulder
of the 550 nm peak. These peaks have molar extinction coefficients of ⬃100 M⫺1 cm⫺1, suggesting these transitions are
ligand field transitions of high-spin Co(II) and that the Co(II)
ion is five-coordinate (37). There were no peaks at ⬃320 nm in
any of the UV-visible spectra of Co(II)-substituted VanX, suggesting that Co(II) does not bind to either of the solvent-accessible cysteines in VanX (38 – 40).
2

Metal Content

C. H. Park, personal communication.

FIG. 2. UV-visible difference spectrum in 50 mM Tris, pH 7.6, of
0.8 mM Co(II)-substituted MBP-VanX prepared in minimal medium at pH 6.8 (A), 0.8 mM Co(II)-substituted MBP-VanX prepared in minimal medium at pH 7.5 (B), and 0.6 mM Co(II)substituted MBP-VanX (gray line) and 0.6 mM Co(II)-substituted
MBP-VanX with 0.6 mM phosphinate (black line) (C).

When Co(II)-substituted MBP-VanX was prepared in minimal medium, pH 7.5, the resulting enzyme exhibited similar
ligand field transitions as in Fig. 2A; however, an additional
feature at 425 nm that had an extinction coefficient of ⬃100
⫺1
M
cm⫺1 was observed (Fig. 2B). The intensity of this peak
implies that it is due to a ligand field transition rather than
from a ligand to metal charge transfer band (expected ⑀ of ⬎500
⫺1
M
cm⫺1) (40). The position of this peak suggests that it arises
from Co(III) in the sample, indicating that Co(II) is air-oxidizing to Co(III) during protein preparation at pH 7.5. The preparation of Co(II)-substituted VanX in minimal medium, pH 6.8,
reduces the amount of air oxidation (Fig. 2A).
In an effort to extend the use of UV-visible spectroscopy to
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FIG. 3. Structure of phosphinate analog of D-Ala-D-Ala.

probe inhibitor binding to VanX, UV-visible spectra were collected on samples of Co(II)-substituted MBP-VanX complexed
with the phosphinate analog of D-Ala-D-Ala (Fig. 3). Previously
Walsh and co-workers (23) reported that this phosphinate is a
slow binding inhibitor of VanX with a Ki value of 1.26 M. Therefore, a 0.5 mM Co(II)-MBP-VanX sample containing equimolar
equivalents of phosphinate inhibitor was expected to result in
⬃100% enzyme-inhibitor complex. In addition, Bussiere and coworkers (1) published a crystal structure of the Zn(II)-VanXphosphinate complex; this structure showed that both phosphinate oxygens coordinate Zn(II) and that Zn(II) is five-coordinate.
Based on this crystal structure and our data on uncomplexed
Co(II)-MBP-VanX, we hypothesized that the intensities of the
Co(II) ligand field transitions would be the same as those of the
uncomplexed enzyme. In addition, we hypothesized that the peak
positions of the ligand field transitions would shift to slightly
longer wavelengths since the phosphinate oxygens were expected
to be weaker field ligands than water. The UV-visible spectrum of
Co(II)-MBP-VanX complexed with the phosphinate inhibitor is
shown in Fig. 2C. As hypothesized, the intensities of the ligand
field transitions in uncomplexed and complexed VanX are the
same, suggesting that Co(II) is five-coordinate in both spectra
(37). The simplest explanation for this observation is that the
phosphinate oxygens replace two solvent molecules in the complexed enzyme. However, we cannot rule out the possibility that
binding of the phosphinate results in the loss of one solvent
molecule and the “shifting” of a chelating Asp-123 to a monodentate binding mode. This behavior has been reported previously
for iron enzymes and has been called the “carboxylate shift” (41).
Efforts to obtain the crystal coordinates of the VanX-phosphinate
complex were unsuccessful as these data are no longer available.2
EPR Spectra of Co(II)-substituted VanX—Initially we attempted to utilize unfused VanX in EPR studies; however,
when we concentrated these samples, VanX precipitated. The
precipitated protein could be diluted with buffer and resolubilized, but the final concentration of soluble VanX was never
greater than 0.3 mM. We, therefore, collected EPR spectra on
precipitated VanX and soluble MBP-VanX samples at 8 K. The
1.6 mM Co(II)-MBP VanX sample exhibited an EPR signal with
turning points at geff(x,y,z) ⫽ 1.92, 3.71, and 5.64 (Fig. 4C).
Computer simulation (Fig. 4D) returned spin Hamiltonian
parameters of MS ⫽ 兩⫾1⁄2典, E/D ⫽ 0.14, greal(x,y) ⫽ 2.37, and
greal(z) ⫽ 2.03 (Fig. 4D). These parameters are not dissimilar to
those from other Co(II)-containing proteins (29, 42) and are
indicative of either a five- or six-coordinate Co(II) center (43).
Six-coordinate Co(II) ions typically exhibit low E/D due to the
high degree of axial symmetry, particularly when unconstrained ligands such as water allow for geometric relaxation,
and examples of this include Co(H2O)62⫹ and the methionyl
aminopeptidase from E. coli (44). The E/D value for VanX,
however, is intermediate for Co(II) centers that are axially
symmetric (E/D ⬃ 0) and for those with the lowest possible
degree of axial symmetry (E/D ⫽ 1⁄3) (30). Thus, the EPR data,
especially when considered along with the extinction coefficients of the electronic absorption ligand field transitions, suggest that the coordination number of Co(II) in Co(II)-MBPVanX is five (29). For five-coordinate systems with no solventderived ligands, such as the leucine phosphonic acid complex of
the aminopeptidase from Vibrio proteolyticus, E/D is signifi-

FIG. 4. EPR simulation of 1.6 mM Co(II) MBP-VanX and precipitated Co(II) MBP-VanX at 8 K. Spectrum A is the measured spectrum of the precipitated enzyme. Spectrum C is the measured spectrum
of the 1.6 mM enzyme. Spectrum E is the subtraction of spectrum C from
spectrum A. Spectra D and F are the simulations of spectra C and E,
respectively. Spectrum B is the sum of spectra D and F.

cantly higher (0.26) than for VanX, and the moderate E/D
(0.14) for VanX may signify the presence of at least one solventderived ligand.
The EPR spectrum of precipitated Co(II)-VanX contains a
component that exhibits markedly higher rhombic distortion of
the axial zero field splitting than that of soluble Co(II)-substituted MBP-VanX and is similar to spectra reported for Co(II)substituted carboxypeptidase A (Fig. 4A) (42). The spectrum of
precipitated Co(II)-VanX appears to result from two components (Fig. 4E, see difference spectrum). The minor component
is indistinguishable from soluble Co(II)-substituted MBP-VanX
(Fig. 4, C and E) and is presumably due to the soluble fraction
of Co(II)-VanX. The major component has geff values of around
1.69, 2.57, and 5.92 (Fig. 4E). The simulation of spectrum E
(Fig. 4) indicates values of E/D ⫽ 0.277, greal(x,y) ⫽ 2.235, and
greal(z) ⫽ 2.112 (Fig. 4F). The similar values of g(x,y) ⫺ g(z) for
both the soluble MBP-VanX and the precipitated VanX suggest
that there is no marked pseudotetragonal elongation or compression in going from the solution phase to the precipitate, but
the higher E/D value for the precipitated VanX indicates a
decrease in axial electronic symmetry, and the narrower lines
suggest a loss of conformational flexibility of the Co(II)-coordinating ligands. These phenomena are consistent with a solvent
ligand being replaced by a rigid ligand and therefore may be
due to Asp-123 providing a bidentate ligand to the metal center
in the precipitated form with the second carboxylate oxygen
atom replacing a coordinated water. The chelate binding mode
of an Asp/Glu residue is precedented in carboxypeptidase A
(45).
The EPR spectrum of the precipitated Co(II)-VanX with
bound phosphinate was essentially due to a single species. The
spectrum exhibited turning points at geff values of 1.86, 2.87,
and 5.78, and computer simulation returned values of E/D ⫽
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FIG. 5. Comparison of two solid VanX spectra without (A) and
with (B) phosphinate inhibitor added.

0.233, g(x,y) ⫽ 2.245, and g(z) ⫽ 2.165 with an MS value of 兩⫾1⁄2典
(Fig. 5B). While these values are certainly sufficiently different
from those of untreated, precipitated VanX to distinguish the
spectrum of the phosphinate complex as being due to a separate chemical species, they suggest a similar chemical structure, viz. a five-coordinate species with low axial electronic
symmetry, possibly due to a bidentate ligand, and low conformational flexibility compared with the uncomplexed soluble
enzyme, probably due to replacement of a water molecule by a
rigid ligand. The crystal structure of VanX with bound phosphinate showed that the inhibitor binds through both phosphinate oxygens (1). This mode of binding is entirely consistent
with the EPR data.
The EPR spectrum of soluble Co(II)-MBP-VanX treated with
phosphinate is markedly different from that of the untreated
enzyme and appears to be made up of two components (Fig.
5A). Simulations of the major component yielded values very
similar to those for phosphinate-treated precipitated VanX: geff
⫽ 1.83, 2.78, and 5.82; E/D ⫽ 0.245; g(x,y) ⫽ 2.252; g(z) ⫽ 2.177;
and MS ⫽ 兩⫾1⁄2典. Based on these values, the major species is
likely due to the bidentate binding mode of phosphinate to
Co(II), similar to that predicted for precipitated Co(II)-VanX
with bound inhibitor. The minor component could not be sufficiently well resolved to extract spin Hamiltonian parameters,
but the presence of an additional sharp feature at low field
suggests that it may be very similar to the major component
and that only subtle geometrical differences exist between the
two species.
EXAFS Spectra of Zn- and Co(II)-substituted VanX—Fourier-transformed EXAFS spectra for Co(II) and Zn(II)-MBPVanX are shown in Fig. 6. Both Fourier-transformed EXAFS
spectra show a narrowly distributed first shell at ⬃2.0 Å and
outer shell scattering consistent with histidine (imidazole) coordination. Single scattering fits indicate that both cobalt and
zinc are coordinated by five nitrogen/oxygen ligands at ⬃ 2.0 Å
(Table II). The size of 2 is suggestive of a heterogeneous first
coordination sphere, such as the His2Asp(OH2)2 coordination
indicated above. However, the data lack sufficient resolution to
define two independent distances. The average bond lengths
are consistent with those expected for five coordination with
mixed nitrogen and oxygen ligands (46). The outer shell scattering for the Zn(II) and Co(II) enzymes is remarkably similar,
indicating the presence of a pair of His ligands in both forms.3
Together with the curve fitting results, the similarity of the
Zn(II)- and Co(II)-MBP-VanX Fourier-transformed EXAFS
spectra demonstrate that zinc and cobalt adopt similar pentacoordinate geometries in the active site of VanX in solution.
The similarity of the data further supports the transferability
of spectroscopic studies on Co(II)-substituted MBP-VanX to
direct investigation of native Zn(II)-VanX.
Comparison of the EXAFS spectra for Co(II)-substituted
3

A. Costello and D. L. Tierney, unpublished results.

FIG. 6. Fourier-transformed EXAFS spectra for Zn(II)-MBPVanX and Co(II)-MBP-VanX in the presence and absence of
phosphinate. First shell fits (dotted lines) are reported in Table II.

MBP-VanX with and without the phosphinate analog of D-Ala(Fig. 6) shows extremely similar first shell coordination
with a slight decrease in average bond length on inhibitor
binding (Table II). Although the two spectra differ dramatically
in signal-to-noise ratio, the low R features are sufficiently
determined to conclude that the overall coordination number of
the Co(II) ion has not changed. The absorption edge energies
for Co(II)-substituted MBP-VanX with and without the inhibitor were 7,718.3 eV, strongly suggesting that the coordination
numbers about Co(II) in both samples are the same and that
the ligand types are similar. Qualitatively the only notable
difference in the Fourier-transformed EXAFS spectra below
R ⫹ ␣ ⫽ 4 Å is the apparent loss of the outer shell scattering
peak at 2.1 Å, a distance consistent with metal-carbon scattering from a coordinated carboxylate (47). Its absence in the
inhibitor complex may indicate a shift in, or the loss of, a
carboxylate ligand. However, the inhibitor bound data are not
of sufficient quality to address this difference quantitatively.
D-Ala

CONCLUSIONS

Based on spectroscopic studies, the metal ion in Co(II)-substituted VanX is five-coordinate. An alternative explanation for
the EPR data would require that the MS ⫽ 兩⫾1⁄2典 spectra observed were, in fact, excited state spectra and that a MS ⫽ 兩⫾3⁄2典
ground state existed due to tetrahedral Co(II). The observation
of only MS ⫽ 兩⫾1⁄2典 at 8 K would require that such a species
exhibited an anomalously low zero field splitting, D. EXAFS
analyses returned markedly better fits for 5-fold coordination
than for 4-fold coordination, although in the absence of other
evidence the assignment could not be taken as unambiguous.
Electronic absorption spectroscopy does, however, appear to
unambiguously preclude tetrahedral coordination. Taken together then, EXAFS, EPR, and electronic absorption spectroscopy are all consistent only with five-coordinate Co(II) in
Co(II)-MBP-VanX.
This result was surprising since the crystal structure of
Zn(II)-VanX showed a four-coordinate Zn(II) in the active site
of VanX (1). There are at least three possible explanations for
this contradictory result. 1) Co(II) in Co(II)-substituted VanX
could have a different coordination number than Zn(II). 2)
Zn(II) could be coordinated by both carboxylate oxygens of
Asp-123, which would be similar to the coordination of Zn(II) by
Glu-72 in carboxypeptidase A (45). 3) There could be an additional solvent (or buffer) molecule in VanX that was not reported in the crystal structure (1). Addressing the first expla-
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TABLE II
EXAFS fitting results for Zn(II)- and Co(II)-MBP-VanX
Fits shown are to Fourier-filtered data; fits to unfiltered data gave similar results.
Sample

Na

Ras

Zn(II)-MBP-VanX
Co(II)-MBP-VanX
Co(II)-MBP-VanX ⫹ phosphinate

5 N/O
5 N/O
5 N/O

2.03
2.00
1.97

as2b

⌬Eoc

Rd

4.8
3.4
4.1

⫺21
⫺26
⫺18

109.0
12.4
22.6

Å

a

Integer coordination number giving the best fit. N/O, nitrogen/oxygen.
Mean square deviation in absorber-scatterer bond length in 10⫺3 Å2.
c
The value of ⌬E0 was allowed to vary for Co(II)-MBP-VanX data sets.
b

冘
冘
N

兵关Re(icalc)]2⫹[Im(icalc)]2}

d

Goodness of fit (R) defined as 1000 ⫻

i⫽1

where N is the number of data points.

N

{[Re(iobs)] ⫹[Im(iobs)] }
2

2

i⫽1

nation, EXAFS studies on Zn(II)-containing and Co(II)containing VanX demonstrate very clearly that these samples
have metal centers with the same coordination number even
though there is slight ambiguity as to what precisely this
number is. In the literature, there are only two examples of
Co(II)-substituted enzymes having a different coordination
number than Zn(II) in the native enzyme (48, 49). The likelihood of a substituted Co(II) ion having a higher coordination
number than the native Zn(II) is not high when the physiochemical properties of these ions are considered. The ionic
radius of Co(II) is 0.02 Å smaller, and the Co(II)-ligand distances are typically shorter than those for native Zn(II) centers
(36); these characteristics would argue for Co(II) having a lower
coordination number rather than a higher one. The spectroscopic data combined indicate that Co(II) must be five-coordinate in VanX. It is clear on experimental grounds and supported by both theoretical considerations and the extensive
literature on Co(II)-substituted Zn(II)-enzymes that Co(II) and
Zn(II) in VanX have the same coordination number. Therefore,
the evidence indicates that Zn(II) in VanX is five-coordinate.
The crystallographic data reported by Park and co-workers
(1) clearly indicate ligands due to His-116 (1 ⫻ nitrogen), His184 (1 ⫻ nitrogen), and Asp-123 (1 ⫻ oxygen at 2.55 Å). An
oxygen atom presumed to be due to water was identified as a
fourth ligand. A second oxygen ligand from Asp-123 was modeled at 3.01 Å from Zn(II). Significant differences between the
EPR spectra of soluble VanX and precipitated VanX clearly
show that the metal center can adopt different geometries
depending on the aggregation state of the protein. It must,
therefore, be at least considered possible that the second oxygen atom of Asp-123 may adopt a slightly different orientation
with respect to Zn(II) in the soluble form of VanX than in the
crystalline state, affording a fifth ligand to Zn(II). The precise
conformational change required to lengthen the Zn(II)-oxygen
bond in the crystalline state will presumably be specific and
dependent on the nature of the global conformational change
that is necessary to maximize the energetic favorability of the
crystal contacts. In contrast, in the precipitated material, there
is insufficient driving force to break the Zn–O bond, although
the geometry of the site is altered. Although technically difficult, EPR and electronic absorption studies of the crystalline
Co(II)-VanX may prove insightful.
The third possible structural scenario consistent with the
crystallographic data is that there is a second solvent ligand to
Zn(II) in soluble VanX. It is possible, although unlikely, that
such a ligand is present in the soluble form but not in the
crystalline form. A more likely explanation is that a second
solvent ligand may be present in the crystalline form but is

undetected. The crystal coordinates were kindly made available for inspection by Dr. Chang H. Park, Abbott Laboratories,
and the quality of the data were insufficient to rule out the
possibility of an additional solvent ligand, particularly if it
were disordered.
In summary, there are rational possible explanations why
the crystal structure and the spectroscopic data may initially
appear at odds. However, the inescapable conclusion from the
spectroscopic work is that Zn(II) in soluble VanX is five-coordinate as is Co(II) in the cobalt-substituted form of the enzyme.
The presence of a five-coordinate Zn(II) or Co(II) in the active
site of VanX may have important catalytic consequences. The
most stable coordination numbers of Zn(II) or Co(II) in proteins
are 4 ⬎ 6 ⬎ 5 (36). It is likely then that 5-fold coordination of
the metal ion represents a state, the entatic state, that is stable
in the resting enzyme but is highly reactive toward a hydrolyzable substrate (50). Mechanistic studies on VanX to probe
the metal center during catalytic turnover are currently in
progress.
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